
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc. is experiencing a positive shift in financial outlook, driven by increased revenue estimates for its key product Brensocatib (Brinsupri NCFB) and anticipated contributions from Treprostinil Palmitil Inhalation Powder (TPIP). The projected worldwide sales for Brensocatib have been raised to approximately $8.5 billion by 2033, reflecting heightened confidence in its near- and long-term potential. Additionally, the company has reduced its terminal decline rate in its discounted cash flow (DCF) calculations, further underscoring positive expectations for the sustainability of its product pipeline.
Bears say
Insmed Inc faces potential delays in the enrollment and completion of clinical studies for its products, ARIKAYCE, brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP), which could severely impact the company's probability of success and overall valuation. The lengthy timelines indicated by competitors suggest that TPIP may not enter the idiopathic pulmonary fibrosis (IPF) market until at least 2034, contingent upon regulatory approvals in 2027. Such uncertainties around product approval and market entry timelines raise concerns about Insmed's ability to capitalize on its product pipeline effectively, contributing to a negative financial outlook for the company.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares